First epinephrine nasal spray clears key FDA hurdle, promising needle-free alternative

The US Food and Drug Administration (FDA) has granted clearance for the first-ever epinephrine nasal spray, offering a needle-free alternative for individuals experiencing anaphylaxis, a severe and potentially life-threatening allergic reaction.

The product, which is called Qtrypta, is a prescription-only drug manufactured by the US-based pharmaceutical company Sedor Pharmaceuticals. The drug works by releasing epinephrine, also known as adrenaline, into the nasal passages, where it can be absorbed into the bloodstream and quickly begin to reverse the symptoms of anaphylaxis.

Anaphylaxis is a severe allergic reaction that can cause symptoms such as difficulty breathing, rapid heartbeat, and a drop in blood pressure. If left untreated, it can be fatal. Currently, the only FDA-approved treatments for anaphylaxis are injectable epinephrine, which requires a needle and syringe and must be administered by a trained healthcare professional or caregiver.

The approval of Qtrypta is significant as it offers a convenient, easy-to-use alternative to injectable epinephrine. According to Sedor Pharmaceuticals, the nasal spray has been shown to be effective in clinical studies, with a rapid onset of action and sustained symptom relief.

The company plans to launch the product in the US in the near future and hopes that it will be covered by insurance. The price of Qtrypta is not yet known.

The development of the epinephrine nasal spray is a promising breakthrough in the field of allergy treatment and could potentially save lives by offering a more accessible and user-friendly option for those experiencing anaphylaxis.

Related Articles

Latest Posts